These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21541780)

  • 1. Anything new in EU pharmacovigilance?
    Garattini S; Bertele' V
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1199-200. PubMed ID: 21541780
    [No Abstract]   [Full Text] [Related]  

  • 2. Looking at EU pharmacovigilance.
    Herxheimer A
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1201-2. PubMed ID: 21750941
    [No Abstract]   [Full Text] [Related]  

  • 3. Getting to grips with the new European Union pharmacovigilance legislation.
    Waller P
    Pharmacoepidemiol Drug Saf; 2011 May; 20(5):544-9. PubMed ID: 21394813
    [No Abstract]   [Full Text] [Related]  

  • 4. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recording and reporting adverse reactions in clinical trials. New legal provisions according to the 12th Law Amending the German Drug Law (AMG) and the Ordinance on GCP (GCP-V)].
    Eckhardt K; Cremer-Schaeffer P; König J; Paeschke N
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):173-80. PubMed ID: 15726458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The new EU legislation on pharmacovigilance and changing models for drug development.
    Callréus T
    Drug Saf; 2011 Jun; 34(6):529-30; author reply 530-1. PubMed ID: 21585224
    [No Abstract]   [Full Text] [Related]  

  • 8. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.
    Francescon S; Fornasier G; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring the impact of the 2012 European pharmacovigilance legislation on additional risk minimization measures.
    Francisca RDC; Zomerdijk IM; Sturkenboom MCJM; Straus SMJM
    Expert Opin Drug Saf; 2018 Oct; 17(10):975-982. PubMed ID: 30107752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harmonization of Pharmacovigilance Regulation in Brazil: Opportunities to Improve Risk Communication.
    Varallo FR; Forgerini M; Herdeiro MT; de Carvalho Mastroianni P
    Clin Ther; 2019 Mar; 41(3):598-603. PubMed ID: 30792075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient Reporting in the EU: Analysis of EudraVigilance Data.
    Banovac M; Candore G; Slattery J; Houÿez F; Haerry D; Genov G; Arlett P
    Drug Saf; 2017 Jul; 40(7):629-645. PubMed ID: 28417320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management system.
    Tanti A; Micallef B; Serracino-Inglott A; Borg JJ
    Expert Opin Drug Saf; 2017 Jan; 16(1):65-76. PubMed ID: 27732110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European legislators tighten rules on drug safety.
    Watson R
    BMJ; 2012 Sep; 345():e6260. PubMed ID: 22991010
    [No Abstract]   [Full Text] [Related]  

  • 14. Patient-Reported Safety Information: A Renaissance of Pharmacovigilance?
    Härmark L; Raine J; Leufkens H; Edwards IR; Moretti U; Sarinic VM; Kant A
    Drug Saf; 2016 Oct; 39(10):883-90. PubMed ID: 27379887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action.
    Radecka A; Loughlin L; Foy M; de Ferraz Guimaraes MV; Sarinic VM; Di Giusti MD; Lesicar M; Straus S; Montero D; Pallos J; Ivanovic J; Raine J
    Drug Saf; 2018 Dec; 41(12):1285-1302. PubMed ID: 30128638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the Safety of Medicines in the European Union: From Signals to Action.
    Potts J; Genov G; Segec A; Raine J; Straus S; Arlett P
    Clin Pharmacol Ther; 2020 Mar; 107(3):521-529. PubMed ID: 31621897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European pharmacovigilance legislation: has it led to implementation of pharmacovigilance inspections?
    Bleumink GS; in't Veld BA; Stricker BH
    Pharmacoepidemiol Drug Saf; 2001; 10(4):339-40. PubMed ID: 11760496
    [No Abstract]   [Full Text] [Related]  

  • 18. Classification of Recombinant Biologics in the EU: Divergence Between National Pharmacovigilance Centers.
    Klein K; De Bruin ML; Broekmans AW; Stolk P
    BioDrugs; 2015 Dec; 29(6):373-9. PubMed ID: 26621793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European agency prepares for new rules to improve drug safety.
    Watson R
    BMJ; 2012 Feb; 344():e955. PubMed ID: 22315299
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.